Answers are grounded in this paper and cite their sources.
Ceftobiprole was non-inferior to ceftriaxone ± linezolid for clinical success at Day 3 according to the current 2020 FDA CABP Guidance.
No takes yet. Share an insight, caveat, or question.
Shorr et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: